Previous 10 | Next 10 |
2024-02-04 08:45:00 ET As Wall Street embarks on the first full week of February, a large number of companies are set to release their earnings reports, providing a crucial glimpse into their financial standing and future outlook. From industry leaders like The Walt Disney Company (...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors. Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and...
2024-01-31 21:10:29 ET Summary Gilead Sciences stock recently saw its biggest one-day correction over the past 10-year history. But I think it's overblown. Read on. The stock sell-off due to Trodelvy's trial disappointment seems disproportionate, given that the drug represents jus...
2024-01-30 13:18:21 ET Earlier this week, Gilead Sciences ( NASDAQ: GILD ) raised its stake in Arcus Arcus Biosciences ( NYSE: RCUS ) to 33% from ~20% by making an additional equity investment of ~$320 million. The new share purchase came priced $21/share, compared to the $1...
2024-01-30 11:14:18 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Without A Clear Growth Path, Gilead Sciences Is A Hold Arcus shares extend ...
2024-01-30 10:22:11 ET More on Arcus Biosciences Arcus Biosciences: Showing There Might Be Something To TIGIT After All Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript Gilead invest...
– New Median Turnaround Time from Leukapheresis to Product Release in U.S. Anticipated to be Reduced from 16 Days to 14 Days – – Continues to Support Kite’s Industry-Leading Overall Turnaround Time and Reliability – – Time to Treat...
NORTHAMPTON, MA / ACCESSWIRE / January 30, 2024 / Gilead Sciences - The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer - and the challenges they face due to stigma and health inequities - come together in the form of a new, intentionally difficult-t...
2024-01-29 18:06:10 ET More on Gilead Sciences, Arcus Biosciences, etc. Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Without A Clear Growth Path, Gilead Sciences Is A Hold ...
– Investment Reinforces Companies’ Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Program – – Additional Equity Investment of $320M, Raising Gilead’s Ownership Stake in Arcus to 33% – – Ame...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...